Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis

被引：0

作者：

Kanwal, Fasiha ^{[1
,2
]}

机构：

[1] Baylor Coll Med, Vet Affairs Hlth Syst Res Ctr Innovat Qual Effecti, Dept Med, Sect Gastroenterol & Hepatol, Houston, TX 77030 USA

[2] Michael E DeBakey Vet Affairs Med Ctr Houston, Houston, TX 77030 USA

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 2024年 / 391卷 / 04期

关键词：

GLP-1 RECEPTOR AGONIST; TIRZEPATIDE; GIP;

D O I：

10.1056/NEJMe2406487

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Metabolic dysfunction-associated steatohepatitis (MASH) is the most common liver disease worldwide, and its prevalence is increasing rapidly.(1) Yet, effective treatments for MASH remain scarce. Obesity plays a central role in MASH. Glucagon-like peptide-1 (GLP-1) receptor agonists are emerging as the most promising antiobesity treatments(2) and could serve as an option for patients with MASH. Few studies have examined the efficacy of GLP-1 receptor agonists in MASH. In a phase 2 trial, treatment with semaglutide - a GLP-1 receptor agonist - led to resolution of steatohepatitis in 40 to 59% of patients but fell short of showing a significant reduction in . . .

引用

页码：371 / 372

页数：2

共 13 条

[1] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity [J].

Aronne, Louis J. ;

Sattar, Naveed ;

Horn, Deborah B. ;

Bays, Harold E. ;

Wharton, Sean ;

Lin, Wen-Yuan ;

Ahmad, Nadia N. ;

Zhang, Shuyu ;

Liao, Ran ;

Bunck, Mathijs C. ;

Jouravskaya, Irina ;

Murphy, Madhumita A. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (01) :38-48

[2] LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept [J].

Coskun, Tamer ;

Sloop, Kyle W. ;

Loghin, Corina ;

Alsina-Fernandez, Jorge ;

Urva, Shweta ;

Bokvist, Krister B. ;

Cui, Xuewei ;

Briere, Daniel A. ;

Cabrera, Over ;

Roell, William C. ;

Kuchibhotla, Uma ;

Moyers, Julie S. ;

Benson, Charles T. ;

Gimeno, Ruth E. ;

D'Alessio, David A. ;

Haupt, Axel .

MOLECULAR METABOLISM, 2018, 18 :3-14

[3] Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes [J].

Heise, Tim ;

DeVries, J. Hans ;

Urva, Shweta ;

Li, Jing ;

Pratt, Edward J. ;

Thomas, Melissa K. ;

Mather, Kieren J. ;

Karanikas, Chrisanthi A. ;

Dunn, Julia ;

Haupt, Axel ;

Milicevic, Zvonko ;

Coskun, Tamer .

DIABETES CARE, 2023, 46 (05) :998-1004

[4] Tirzepatide Once Weekly for the Treatment of Obesity [J].

Jastreboff, Ania M. ;

Aronne, Louis J. ;

Ahmad, Nadia N. ;

Wharton, Sean ;

Connery, Lisa ;

Alves, Breno ;

Kiyosue, Arihiro ;

Zhang, Shuyu ;

Liu, Bing ;

Bunck, Mathijs C. ;

Stefanski, Adam .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (03) :205-216

[5] Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis [J].

Loomba, Rohit ;

Hartman, Mark L. ;

Lawitz, Eric J. ;

Vuppalanchi, Raj ;

Boursier, Jerome ;

Bugianesi, Elisabetta ;

Yoneda, Masato ;

Behling, Cynthia ;

Cummings, Oscar W. ;

Tang, Yuanyuan ;

Brouwers, Bram ;

Robins, Deborah A. ;

Nikooie, Amir ;

Bunck, Mathijs C. ;

Haupt, Axel ;

Sanyal, Arun J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04) :299-310

[6] Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial [J].

Loomba, Rohit ;

Abdelmalek, Manal F. ;

Armstrong, Matthew J. ;

Jara, Maximilian ;

Kjaer, Mette Skalshoi ;

Krarup, Niels ;

Lawitz, Eric ;

Ratziu, Vlad ;

Sanyal, Arun J. ;

Schattenberg, Jorn M. ;

Newsome, Philip N. .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2023, 8 (06) :511-522

[7] A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis [J].

Newsome, Philip N. ;

Buchholtz, Kristine ;

Cusi, Kenneth ;

Linder, Martin ;

Okanoue, Takeshi ;

Ratziu, Vlad ;

Sanyal, Arun J. ;

Sejling, Anne-Sophie ;

Harrison, Stephen A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12) :1113-1124

[8] The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis [J].

Riazi, Kiarash ;

Azhari, Hassan ;

Charette, Jacob H. ;

Underwood, Fox E. ;

King, James A. ;

Afshar, Elnaz Ehteshami ;

Swain, Mark G. ;

Congly, Stephen E. ;

Kaplan, Gilaad G. ;

Shaheen, Abdel-Aziz .

LANCET GASTROENTEROLOGY & HEPATOLOGY, 2022, 7 (09) :851-861

[9] Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial [J].

Rosenstock, Julio ;

Wysham, Carol ;

Frias, Juan P. ;

Kaneko, Shizuka ;

Lee, Clare J. ;

Lando, Laura Fernandez ;

Mao, Huzhang ;

Cui, Xuewei ;

Karanikas, Chrisanthi A. ;

Thieu, Vivian T. .

LANCET, 2021, 398 (10295) :143-155

[10] A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis [J].

Sanyal, Arun J. ;

Bedossa, Pierre ;

Fraessdorf, Mandy ;

Neff, Guy W. ;

Lawitz, Eric ;

Bugianesi, Elisabetta ;

Anstee, Quentin M. ;

Hussain, Samina Ajaz ;

Newsome, Philip N. ;

Ratziu, Vlad ;

Hosseini-Tabatabaei, Azadeh ;

Schattenberg, Jorn M. ;

Noureddin, Mazen ;

Alkhouri, Naim ;

Younes, Ramy .

NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (04) :311-319

← 1 2 →